Haemodynamic and metabolic effects rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine

Nicola De Luca, Raffael Izzo, Dario Fontana, Gianluigi Iovino, Luigi Argenziano, Carmine Vecchione, Bruno Trimarco

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Objective: To compare the effects of rilmenidine with those of amlodipine on blood pressure, glucose metabolism, plasma lipid concentration and fibrinolysis parameters. Design: A four-month randomized double-blind, parallel group study. Patients and methods: Obese hypertensive patients with hypertriglyceridaemia (≥ 2.3 mmol/l) and impaired glucose tolerance (OMS-ADA) were included (n = 52). A placebo run-in period of 2 weeks was followed by 4 months of double-blind treatment with either rilmenidine or amlodipine. Blood pressure was recorded using a mercury sphygmomanometer. Glucose metabolism was evaluated by an oral glucose tolerance test. Results: Of the 52 patients recruited, 47 (21 rilmenidine and 26 amlodipine) completed the 4-month treatment period. The intention-to-treat analysis showed a comparable reduction in systolic and diastolic blood pressure (SBP, DBP) with the two anti-hypertensive treatments (rilmenidine -13.9/-13.5 mmHg; amlodipine -17.6/- 15.0 mmHg). Insulin concentrations under basal conditions and 2 h after a standard oral glucose load did not change significantly after treatment in both groups. Plasma glucose under basal conditions and 2 h after a standard oral glucose load as well as the area under the plasma glucose concentration curve tended to decrease in the rilmenidine group and to increase in the amlodipine group so that the changes in these parameters were significantly different between the two study groups (P = 0.041, P = 0.042 and P = 0.015, respectively). Plasminogen activator inhibitor type 1 (PAI-1) antigen and PAI-1 activity were only decreased in the rilmenidine group (not statistically significant). Conclusion: Our results demonstrate that rilmenidine and amlodipine have a comparable anti-hypertensive effect but only rilmenidine is able to improve glucose metabolism. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish
Pages (from-to)1515-1522
Number of pages8
JournalJournal of Hypertension
Volume18
Issue number10
Publication statusPublished - 2000

Fingerprint

rilmenidine
Metabolic Syndrome X
Amlodipine
Double-Blind Method
Hemodynamics
Glucose
Blood Pressure
Plasminogen Activator Inhibitor 1
Antihypertensive Agents
Sphygmomanometers
Intention to Treat Analysis
Glucose Intolerance
Hypertriglyceridemia
Fibrinolysis
Therapeutics
Glucose Tolerance Test
Mercury
Lipid Metabolism
Blood Glucose

Keywords

  • Imidazoline receptors
  • Insulin resistance
  • Obesity
  • PAI-1
  • Plasminogen activator inhibitor type 1

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology

Cite this

Haemodynamic and metabolic effects rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. / De Luca, Nicola; Izzo, Raffael; Fontana, Dario; Iovino, Gianluigi; Argenziano, Luigi; Vecchione, Carmine; Trimarco, Bruno.

In: Journal of Hypertension, Vol. 18, No. 10, 2000, p. 1515-1522.

Research output: Contribution to journalArticle

De Luca, Nicola ; Izzo, Raffael ; Fontana, Dario ; Iovino, Gianluigi ; Argenziano, Luigi ; Vecchione, Carmine ; Trimarco, Bruno. / Haemodynamic and metabolic effects rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine. In: Journal of Hypertension. 2000 ; Vol. 18, No. 10. pp. 1515-1522.
@article{aa11f8b014b04018b39b192aef2c9388,
title = "Haemodynamic and metabolic effects rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine",
abstract = "Objective: To compare the effects of rilmenidine with those of amlodipine on blood pressure, glucose metabolism, plasma lipid concentration and fibrinolysis parameters. Design: A four-month randomized double-blind, parallel group study. Patients and methods: Obese hypertensive patients with hypertriglyceridaemia (≥ 2.3 mmol/l) and impaired glucose tolerance (OMS-ADA) were included (n = 52). A placebo run-in period of 2 weeks was followed by 4 months of double-blind treatment with either rilmenidine or amlodipine. Blood pressure was recorded using a mercury sphygmomanometer. Glucose metabolism was evaluated by an oral glucose tolerance test. Results: Of the 52 patients recruited, 47 (21 rilmenidine and 26 amlodipine) completed the 4-month treatment period. The intention-to-treat analysis showed a comparable reduction in systolic and diastolic blood pressure (SBP, DBP) with the two anti-hypertensive treatments (rilmenidine -13.9/-13.5 mmHg; amlodipine -17.6/- 15.0 mmHg). Insulin concentrations under basal conditions and 2 h after a standard oral glucose load did not change significantly after treatment in both groups. Plasma glucose under basal conditions and 2 h after a standard oral glucose load as well as the area under the plasma glucose concentration curve tended to decrease in the rilmenidine group and to increase in the amlodipine group so that the changes in these parameters were significantly different between the two study groups (P = 0.041, P = 0.042 and P = 0.015, respectively). Plasminogen activator inhibitor type 1 (PAI-1) antigen and PAI-1 activity were only decreased in the rilmenidine group (not statistically significant). Conclusion: Our results demonstrate that rilmenidine and amlodipine have a comparable anti-hypertensive effect but only rilmenidine is able to improve glucose metabolism. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Imidazoline receptors, Insulin resistance, Obesity, PAI-1, Plasminogen activator inhibitor type 1",
author = "{De Luca}, Nicola and Raffael Izzo and Dario Fontana and Gianluigi Iovino and Luigi Argenziano and Carmine Vecchione and Bruno Trimarco",
year = "2000",
language = "English",
volume = "18",
pages = "1515--1522",
journal = "Journal of Hypertension",
issn = "0263-6352",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Haemodynamic and metabolic effects rilmenidine in hypertensive patients with metabolic syndrome X. A double-blind parallel study versus amlodipine

AU - De Luca, Nicola

AU - Izzo, Raffael

AU - Fontana, Dario

AU - Iovino, Gianluigi

AU - Argenziano, Luigi

AU - Vecchione, Carmine

AU - Trimarco, Bruno

PY - 2000

Y1 - 2000

N2 - Objective: To compare the effects of rilmenidine with those of amlodipine on blood pressure, glucose metabolism, plasma lipid concentration and fibrinolysis parameters. Design: A four-month randomized double-blind, parallel group study. Patients and methods: Obese hypertensive patients with hypertriglyceridaemia (≥ 2.3 mmol/l) and impaired glucose tolerance (OMS-ADA) were included (n = 52). A placebo run-in period of 2 weeks was followed by 4 months of double-blind treatment with either rilmenidine or amlodipine. Blood pressure was recorded using a mercury sphygmomanometer. Glucose metabolism was evaluated by an oral glucose tolerance test. Results: Of the 52 patients recruited, 47 (21 rilmenidine and 26 amlodipine) completed the 4-month treatment period. The intention-to-treat analysis showed a comparable reduction in systolic and diastolic blood pressure (SBP, DBP) with the two anti-hypertensive treatments (rilmenidine -13.9/-13.5 mmHg; amlodipine -17.6/- 15.0 mmHg). Insulin concentrations under basal conditions and 2 h after a standard oral glucose load did not change significantly after treatment in both groups. Plasma glucose under basal conditions and 2 h after a standard oral glucose load as well as the area under the plasma glucose concentration curve tended to decrease in the rilmenidine group and to increase in the amlodipine group so that the changes in these parameters were significantly different between the two study groups (P = 0.041, P = 0.042 and P = 0.015, respectively). Plasminogen activator inhibitor type 1 (PAI-1) antigen and PAI-1 activity were only decreased in the rilmenidine group (not statistically significant). Conclusion: Our results demonstrate that rilmenidine and amlodipine have a comparable anti-hypertensive effect but only rilmenidine is able to improve glucose metabolism. (C) 2000 Lippincott Williams and Wilkins.

AB - Objective: To compare the effects of rilmenidine with those of amlodipine on blood pressure, glucose metabolism, plasma lipid concentration and fibrinolysis parameters. Design: A four-month randomized double-blind, parallel group study. Patients and methods: Obese hypertensive patients with hypertriglyceridaemia (≥ 2.3 mmol/l) and impaired glucose tolerance (OMS-ADA) were included (n = 52). A placebo run-in period of 2 weeks was followed by 4 months of double-blind treatment with either rilmenidine or amlodipine. Blood pressure was recorded using a mercury sphygmomanometer. Glucose metabolism was evaluated by an oral glucose tolerance test. Results: Of the 52 patients recruited, 47 (21 rilmenidine and 26 amlodipine) completed the 4-month treatment period. The intention-to-treat analysis showed a comparable reduction in systolic and diastolic blood pressure (SBP, DBP) with the two anti-hypertensive treatments (rilmenidine -13.9/-13.5 mmHg; amlodipine -17.6/- 15.0 mmHg). Insulin concentrations under basal conditions and 2 h after a standard oral glucose load did not change significantly after treatment in both groups. Plasma glucose under basal conditions and 2 h after a standard oral glucose load as well as the area under the plasma glucose concentration curve tended to decrease in the rilmenidine group and to increase in the amlodipine group so that the changes in these parameters were significantly different between the two study groups (P = 0.041, P = 0.042 and P = 0.015, respectively). Plasminogen activator inhibitor type 1 (PAI-1) antigen and PAI-1 activity were only decreased in the rilmenidine group (not statistically significant). Conclusion: Our results demonstrate that rilmenidine and amlodipine have a comparable anti-hypertensive effect but only rilmenidine is able to improve glucose metabolism. (C) 2000 Lippincott Williams and Wilkins.

KW - Imidazoline receptors

KW - Insulin resistance

KW - Obesity

KW - PAI-1

KW - Plasminogen activator inhibitor type 1

UR - http://www.scopus.com/inward/record.url?scp=0033785211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033785211&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 1515

EP - 1522

JO - Journal of Hypertension

JF - Journal of Hypertension

SN - 0263-6352

IS - 10

ER -